Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)

Zoetis' (ZTS) quarterly Liabilities and Shareholders Equity came in at $15.2 billion in Q1 2026, up 7.49% year-on-year from $14.1 billion in Q1 2025, and down 2.17% on a QoQ basis from $15.5 billion in Q4 2025.

Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends

Zoetis (ZTS) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $15.2 billion in Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 7.49% year-over-year to $15.2 billion in Q1 2026; TTM through Mar 2026 was $60.3 billion, a 6.09% increase from a year earlier, with the FY2025 full-year figure at $15.5 billion, up 9.08% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $15.2 billion, down from $15.5 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ZTS reached as high as $15.5 billion in Q4 2025 and fell as low as $13.7 billion in Q3 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $14.3 billion across 5 years, with a median of $14.2 billion in 2024.
  • Across the five-year window, Liabilities and Shareholders Equity fell 4.28% in 2023 and grew 9.08% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $14.9 billion in 2022, then slipped by 4.28% to $14.3 billion in 2023, then declined by 0.6% to $14.2 billion in 2024, then climbed by 9.08% to $15.5 billion in 2025, then decreased by 2.17% to $15.2 billion in 2026.
  • Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $15.2 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 6.71 Bn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - 25.35 Mn
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 13.22 Bn
10 Vireo Growth 10.53 Bn 10.38 Bn 59.30 Mn 928.80 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.15 Bn
Dec 31, 2025 15.49 Bn
Sep 30, 2025 15.16 Bn
Jun 30, 2025 14.48 Bn
Mar 31, 2025 14.10 Bn
Dec 31, 2024 14.20 Bn
Sep 30, 2024 14.36 Bn
Jun 30, 2024 14.17 Bn
Mar 31, 2024 14.35 Bn
Dec 31, 2023 14.29 Bn
Sep 30, 2023 14.11 Bn
Jun 30, 2023 13.75 Bn
Mar 31, 2023 13.75 Bn
Dec 31, 2022 14.93 Bn
Sep 30, 2022 13.67 Bn
Jun 30, 2022 13.77 Bn
Mar 31, 2022 13.86 Bn
Dec 31, 2021 13.90 Bn
Sep 30, 2021 13.71 Bn
Jun 30, 2021 14.07 Bn